natgillin/translations-raw huggingface dataset:
Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Nesteroidna protivnetna zdravila: pri sočasnem zdravljenju z antagonisti angiotenzina II in nesteroidnimi protivnetnimi zdravili (NSAID) (npr. selektivnimi COX-2 zaviralci, acetilsalicilno kislino (> 3 g/dan) in neselektivnimi NSAID) se lahko antihipertenzivni učinek zmanjša.
NDEA Limit in ppm in API
Meja za NDEA v ppm v učinkovini
CoAprovel is not recommended for use in children and adolescents because the safety and efficacy have not been established.
Varnost in učinkovitost zdravila CoAprovel nista bili dokazani, zato uporaba pri otrocih in mladostnikih ni priporočljiva.
Following oral administration of CoAprovel, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Po peroralnem jemanju zdravila CoAprovel je biološka uporabnost irbesartana približno 60-80%, hidroklorotiazida pa 50-80%.
Side effects reported in clinical studies for patients treated with CoAprovel were:
Med kliničnimi študijami so pri bolnikih, ki so se zdravili z zdravilom CoAprovel, poročali o naslednjih neželenih učinkih:
Preparations containing lithium should not be taken with CoAprovel without close supervision by your doctor.
Zdravila, ki vsebujejo litij, smete z zdravilom CoAprovel jemati le pod strogim zdravniškim nadzorom.
Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Dodatni podatki o medsebojnem delovanju z irbesartanom: v kliničnih študijah hidroklorotiazid ni vplival na farmakokinetiko irbesartana.
Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day).
Irbesartan je povzročil hiperplazijo/hipertrofijo jukstaglomerulnih celic (pri podganah po odmerku ≥ 90 mg/kg/dan in pri opicah po odmerku ≥ 10 mg/kg/dan).
Primary aldosteronism: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system.
Primarni aldosteronizem: pri bolnikih s primarnim aldosteronizmom zdravljenje z antihipertenzivi, ki zavirajo sistem renin-angiotenzin, običajno ni učinkovito.
depression, sleep disturbances
depresija, motnje spanja
Blood and lymphatic system disorders:
Bolezni krvi in limfatičnega sistema:
Food does not affect the bioavailability of CoAprovel.
Sočasno uživanje hrane na biološko uporabnost zdravila CoAprovel ne vpliva.
Tables 2 and 3 below detail the adverse reactions reported with the individual components of CoAprovel.
V tabeli 2 in 3 so navedeni neželeni učinki, o katerih so poročali pri uporabi posamezne zdravilne učinkovine zdravila CoAprovel.
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).
Nemelanomski kožni rak: Na podlagi obstoječih podatkov epidemioloških študij so ugotovili, da obstaja razmerje med kumulativnim odmerkom hidroklorotiazida in nemelanomskim kožnim rakom (glejte tudi poglavji 4.4 in 5.1).
NDMA Limit in ng/day
Meja za NDMA v ng/dan
Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan (blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing cells) and occur also with angiotensin converting enzyme inhibitors.
Večina naštetih učinkov je verjetno posledica farmakološke aktivnosti irbesartana (blokade z angiotenzinom II inducirane inhibicije sproščanja renina in stimulacije celic, v katerih renin nastaja), in se pojavijo tudi med uporabo zaviralcev angiotenzin-konvertaze.
jaundice (intrahepatic cholestatic jaundice)
zlatenica (intrahepatska holestatska zlatenica)
NDEA Limit in ng/day
Meja za NDEA v ng/dan
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.
Druge interakcije: tiazidni diuretiki lahko zvečajo hiperglikemični učinek blokatorjev beta in diazoksida.
dyspepsia, dysgeusia
dispepsija, paragevzija
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide;
Nedepolarizirajoči relaksanti skeletnega mišičja (npr. tubokurarin): hidroklorotiazid lahko potencira delovanje nedepolarizirajočih relaksantov skeletnega mišičja.
If you have any further questions, ask your doctor or pharmacist.
 Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom ali s farmacevtom.
The blood pressure lowering effect of irbesartan in combination with hydrochlorothiazide is apparent after the first dose and substantially present within 1-2 weeks, with the maximal effect occurring by 68 weeks.
Krvni tlak se zniža že po prvem odmerku irbesartana in hidroklorotiazida, izrazito v 1-2 tednih, najbolj pa v 6-8 tednih.
Forty-seven percent (47.2%) of patients on the combination achieved trough SeDBP < 90 mmHg compared to 33.2% of patients on irbesartan (p = 0.0005).
Vrednost SeDBP < 90 mmHg je bila dosežena pri sedeminštiridesetih odstotkih (47,2%) bolnikov, ki so se zdravili s kombinacijo in 33,2% bolnikov, ki so se zdravili z irbesartanom (p = 0,0005).
The MAH shall complete, within the stated timeframe, the below measures:
Imetnik dovoljenja za promet z zdravilom mora v določenem časovnem okviru izvesti naslednje ukrepe:
Other antihypertensive agents: the antihypertensive effect of CoAprovel may be increased with the concomitant use of other antihypertensive agents.
Drugi antihipertenzivi: antihipertenzijski učinek zdravila CoAprovel se lahko med sočasno uporabo drugih antihipertenzivov zveča.
There is no experience regarding the administration of CoAprovel in patients with a recent kidney transplantation.
Izkušenj z uporabo zdravila CoAprovel pri bolnikih po nedavni presaditvi ledvice ni.
hyperkalaemia
hiperkaliemija
Side effects associated with hydrochlorothiazide alone Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.
Neželeni učinki, ki so povezani z jemanjem hidroklorotiazida samega Izguba apetita; draženje želodca; krči v želodcu; zaprtost; zlatenica (rumeno obarvanje kože in/ali očesnih beločnic); vnetje trebušne slinavke, za katerega je značilna huda bolečina v zgornjem predelu trebuha, ki jo pogosto spremlja slabost in bruhanje; motnje spanja; depresija; zamegljen vid; zmanjšanje števila belih krvnih celic, ki ima za posledico lahko pogostejše okužbe in zvišano telesno temperaturo; zmanjšanje števila trombocitov (krvnih celic, pomembnih za strjevanje krvi), zmanjšanje števila rdečih krvnih celic (anemija) za katero je značilna utrujenost, glavobol, zasoplost pri telesni aktivnosti, omotica in bledica; bolezen ledvic; bolezen pljuč, vključno s pljučnico in kopičenjem tekočine v pljučih; večja občutljivost kože za sončno svetlobo; vnetje krvnih žil; kožna bolezen za katero je značilno luščenje kože po celem telesu; kožni eritematozni lupus, ki se kaže z izpuščajem po obrazu, vratu in lasišču; alergijske reakcije; oslabelost in krči mišic; spremembe srčnega utripa; znižanje krvnega tlaka po spremembi položaja telesa; otekanje žlez slinavk; zvišanje vrednosti sladkorja v krvi; sladkor v urinu; zvišanje vrednosti nekaterih maščob v krvi; zvišanje vrednosti sečne kisline v krvi, kar lahko povzroči protin.
14 tablets 28 tablets 30 tablets 56 tablets 56 x 1 tablets 84 tablets 90 tablets 98 tablets
14 tablet 28 tablet 30 tablet 56 tablet 56 x 1 tableta 84 tablet 90 tablet 98 tablet
Musculoskeletal and connective tissue disorders:
Bolezni mišično-skeletnega sistema in vezivnega tkiva:
decreases in serum potassium and sodium
znižanje vrednosti serumskega kalija in natrija
You should also tell your doctor: if you are on a low-salt diet if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in CoAprovel) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking CoAprovel.
Svojemu zdravniku morate tudi povedati:  če imate dieto z zmanjšanim vnosom soli če imate znake, kot so nenormalna žeja, suha usta, splošna oslabelost, zaspanost, bolečine ali krči v mišicah, siljenje na bruhanje, bruhanje ali nenormalno hiter srčni utrip, ki so lahko posledica prevelikega učinka hidroklorotiazida (ki ga vsebuje zdravilo CoAprovel) če vaša koža postane bolj občutljiva na sonce oziroma se znaki sončnih opeklin (kot so pordelost, srbenje, otekline, pojav mehurjev) pojavijo hitreje kot normalno  če imate predvideno operacijo (kirurški poseg) ali boste prejeli anestetik če se med jemanjem zdravila CoAprovel pojavijo spremembe vida ali bolečina v enem ali obeh očesih.
In these patients, an incremental blood pressure lowering effect was observed for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) (13.3 and 8.3 mm Hg, respectively).
Pri teh bolnikih so opazili stopnjevanje učinka na znižanje sistoličnega in diastoličnega krvnega tlaka (sistoličnega za 13,3 mmHg, diastoličnega za 8,3 mmHg).
14 tablets 28 tablets 56 tablets 56 x 1 tablets 98 tablets
14 tablet 28 tablet 56 tablet 56 x 1 tableta 98 tablet
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis.
Po prevelikem odmerjanju hidroklorotiazida se pojavita izguba elektrolitov (hipokaliemija, hipokloremija, hiponatriemija) in dehidracija, ki sta posledica čezmerne diureze.
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with CoAprovel.
Dodatni podatki o posameznih učinkovinah: poleg zgoraj naštetih neželenih učinkov, ki se lahko pojavijo med uporabo kombiniranega zdravila, se utegnejo med jemanjem zdravila CoAprovel pojaviti tudi neželeni učinki, o katerih so predhodno poročali pri jemanju posamezne zdravilne učinkovine.
CoAprovel is a combination of two active substances, irbesartan and hydrochlorothiazide.
Zdravilo CoAprovel je kombinacija dveh zdravilnih učinkovin, irbesartana in hidroklorotiazida.
CoAprovel contains lactose.
Zdravilo CoAprovel vsebuje laktozo.
Acute Myopia and Secondary Acute Angle-Closure Glaucoma: sulfonamide drugs or sulfonamide derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angleclosure glaucoma.
Akutna kratkovidnost in sekundarni akutni glavkom z zaprtim zakotjem: zdravila, ki vsebujejo sulfonamide ali njihove derivate lahko povzročijo idiosinkratično reakcijo s posledično prehodno kratkovidnostjo in akutnim glavkomom z zaprtim zakotjem.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS): there is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Dvojna blokada sistema renin-angiotenzin-aldosteron (RAAS): obstajajo dokazi, da sočasna uporaba zaviralcev ACE, blokatorjev receptorjev angiotenzina II ali aliskirena poveča tveganje za hipotenzijo, hiperkaliemijo in zmanjšano delovanje ledvic (vključno z akutno odpovedjo ledvic).
CoAprovel should not be given to children under 18 years of age.
Otroci, mlajši od 18 let, zdravila CoAprovel ne smejo jemati.
Additional information on hydrochlorothiazide interactions: when administered concurrently, the following medicinal products may interact with thiazide diuretics:
Dodatni podatki o medsebojnem delovanju s hidroklorotiazidom: ob sočasni uporabi se lahko pojavijo interakcije med tiazidnimi diuretiki in naslednjimi zdravili:
interstitial nephritis, renal dysfunction
intersticijski nefritis, motnje delovanja ledvic
Hypotension - Volume-depleted patients: CoAprovel has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Hipotenzija - zmanjšan intravaskularni volumen: simptomatska hipotenzija se pri bolnikih z zvišanim krvnim tlakom, ki jemljejo zdravilo CoAprovel, nimajo pa drugih dejavnikov tveganja za hipotenzijo, pojavi le redko.
anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria
anafilaktične reakcije, toksična epidermalna nekroliza, nekrotizirajoči angiitis (vaskulitis, vnetje kožnih žil ali mezgovnic), reakcije, podobne kožnemu eritematoznemu lupusu, reaktivacija kožnega eritematoznega lupusa, fotosenzitivne reakcije, izpuščaj, urtikarija
Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with CoAprovel.
Tiazidi zmanjšujejo ledvični očistek litija, zato se med zdravljenjem z zdravilom CoAprovel poveča nevarnost zastrupitve z litijem.
Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Po peroralni ali intravenski uporabi irbesartana 14C je v obtoku 80 do 85% nespremenjene učinkovine.
Common side effects (may affect up to 1 in 10 people): nausea/vomiting abnormal urination fatigue dizziness (including when getting up from a lying or sitting position) blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).
siljenje na bruhanje/bruhanje nenormalno uriniranje utrujenost omotica (tudi pri vstajanju iz ležečega ali sedečega položaja) krvne preiskave lahko pokažejo zvišanje vrednosti encima, ki kaže na delovanje mišic in srca (encim kreatin-kinaza), ali zvišanje vrednosti snovi, ki so merilo delovanja ledvic (dušik sečnine v krvi, kreatinin).
The active substances are irbesartan and hydrochlorothiazide.
Zdravilni učinkovini sta irbesartan in hidroklorotiazid.
Your doctor will instruct you how to switch from the previous treatment to CoAprovel.
Povedal vam bo tudi, kako prenehati jemati dosedanje zdravilo in kako začeti zdravljenje z zdravilom CoAprovel.
14 - 28 - 56 - 84 - 98 tablets: Mon
14 - 28 - 56 - 84 - 98 tablet: Pon
Carbamazepine: concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatraemia.
Karbamazepin: sočasna uporaba karbamazepina in hidroklorotiazida je povezana s tveganjem za pojav simptomatske hiponatriemije, zato je v tem primeru treba spremljati vrednosti elektrolitov.
Non-melanoma skin cancer:
Nemelanomski kožni rak:
There is no clinical experience with CoAprovel in patients with hepatic impairment.
Kliničnih izkušenj z uporabo zdravila CoAprovel pri bolnikih z jetrno okvaro ni.
General disorders and administration site conditions:
Splošne težave in spremembe na mestu aplikacije:
While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angleclosure glaucoma have been reported so far with hydrochlorothiazide.
Hidroklorotiazid je sicer sulfonamid, vendar pa so do sedaj med njegovo uporabo poročali le o posameznih primerih akutnega glavkoma z zaprtim zakotjem.
Due to the hydrochlorothiazide component, CoAprovel is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/min).
Zdravilo CoAprovel vsebuje hidroklorotiazid, zato za bolnike s hudo motenim delovanjem ledvic (očistek kreatinina < 30 ml/min) ni primeren.
Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
Neželeni učinki, katerih pogostnost ni znana, so: glavobol, zvonjenje v ušesih, kašelj, motnje okušanja, prebavne motnje, bolečine v sklepih in mišicah, nenormalno delovanje jeter, okvara delovanja ledvic, zvišanje vrednosti kalija v krvi in alergijske reakcije, kot so izpuščaj, koprivnica in lokalizirana oteklina obraza, ustnic, ust, jezika ali žrela.
The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).
Poleg tega bi bilo morda treba ponovo premisliti o uporabi hidroklorotiazida pri bolnikih, ki so že preboleli nemelanomskega kožnega raka (glejte tudi poglavje
Twelve percent (12%) of patients were diabetic, 34% were hyperlipidemic and the most frequent cardiovascular condition was stable angina pectoris in 3.5% of the participants.
Najpogostejša bolezen srca je bila stabilna angina pektoris, ki jo je imelo 3,5% vključenih bolnikov.
CoAprovel is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Zdravilo CoAprovel je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of CoAprovel with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m²) (see sections 4.5 and 5.1).
Huda jetrna okvara, biliarna ciroza ali holestaza+ Sočasna uporaba zdravila CoAprovel in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (hitrost glomerularne filtracije < 60 ml/min/1,73 m2) (glejte poglavji 4.5 in 5.1).
Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia, and hypochloremic alkalosis).
Tiazidni diuretiki, vključno s hidroklorotiazidom, lahko porušijo ravnovesje tekočin ali elektrolitov (hipokaliemija, hiponatriemija in hipokloremična alkaloza).
14 - 28 - 56 - 98 tablets: Mon
14 - 28 - 56 - 98 tablet: Pon
transient blurred vision, xanthopsia, acute myopia and secondary acute angle-closure glaucoma
prehodno zamegljen vid, ksantopsija, akutna kratkovidnost in sekundarni akutni glavkom z zaprtim zakotjem
(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.
Tudi resni interesantni neželeni učinki (hiperkaliemija, hipotenzija in disfunkcija ledvic) so bili v skupini, ki je prejemala aliskiren, pogostejši kot v skupini, ki je prejemala placebo.
aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
aplastična anemija, zavora delovanja kostnega mozga, nevtropenija/agranulocitoza, hemolitična anemija, levkopenija, trombocitopenija
CoAprovel is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.
Zdravilo CoAprovel uporabljamo za zdravljenje zvišanega krvnega tlaka, če pri zdravljenju samo z irbesartanom ali samo s hidroklorotiazidom krvni tlak ni bil zadostno nadzorovan.
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with CoAprovel (see section 4.5).
Pri hkratnem zdravljenju z diuretiki, ki varčujejo kalij, pripravki s kalijem, nadomestki soli, ki vsebujejo kalij, in zdravilom CoAprovel je potrebna posebna previdnost (glejte poglavje 4.5).
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed): kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system; slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit); stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
Pri podganah in opicah, ki so prejemale kombinacijo 10 mg irbesartana in 10 mg hidroklorotiazida na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi uporabe ene učinkovine ali kombiniranega dajanja pojavile naslednje spremembe:  ledvične spremembe so se kazale kot blago zvečanje sečnine in kreatinina v serumu ter hiperplazija/hipertrofija jukstaglomerulnega aparata, kar je neposredna posledica interakcije med irbesartanom in sistemom renin-angiotenzin;  blago zmanjšanje eritrocitnih parametrov (eritrocitov, hemoglobina in hematokrita);  pri nekaj podganah, ki so v študiji toksičnosti 6 mesecev dobivale po 90 mg irbesartana na kg/dan in 90 mg hidroklorotiazida na kg/dan ter kombinacijo irbesartana in hidroklorotiazida (10 mg/10 mg/kg/dan), so opazili spremembo barve želodca, razjede in fokalno nekrozo želodčne sluznice; teh lezij pri opicah ni bilo; znižanje kalija v serumu med uporabo hidroklorotiazida, ki je bilo med kombiniranim dajanjem z irbesartanom manj izrazito.
In addition to the side effects listed above, chest pain, severe allergic reactions (anaphylactic shock), and decrease in the number of platelets (a blood cell essential for the clotting of the blood) have also been reported.
Neželeni učinki, ki so povezani z jemanjem irbesartana samega Poleg zgoraj naštetih neželenih učinkov so poročali tudi o pojavu bolečine v prsnem košu, hudih alergijskih reakcijah (anafilaktični šok) in zmanjšanju števila trombocitov (krvne celice, ki so nujne za strjevanje krvi).
orthostatic dizziness
ortostatska omotica
The use of CoAprovel during breast feeding is not recommended.
Uporaba zdravila CoAprovel med dojenjem ni priporočljiva.
Therefore, the combination of lithium and CoAprovel is not recommended (see section 4.4).
Sočasna uporaba litija in zdravila CoAprovel zato ni priporočljiva (glejte poglavje 4.4).
Unit dose blister packs of 56 x 1 film-coated tablet for delivery in hospitals are also available.
Za uporabo v bolnišnicah so na voljo tudi v enoodmernih pretisnih omotih s 56 x 1 filmsko obloženo tableto.